Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.

[1]  C. Denton,et al.  Pulmonary hypertension in systemic sclerosis. , 2003, Rheumatic diseases clinics of North America.

[2]  C. Denton,et al.  Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. , 2001, Rheumatology.

[3]  S. Nishio,et al.  [Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue]. , 2001, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[4]  N. Galiè.  Do we need controlled clinical trials in pulmonary arterial hypertension? , 2001, The European respiratory journal.

[5]  H. Farber,et al.  Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. , 2000, American journal of respiratory and critical care medicine.

[6]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[7]  L. Hillis,et al.  Congenital heart disease in adults : Second of two parts , 2000 .

[8]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[9]  Y. Okano,et al.  Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.

[10]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[11]  S. Rich,et al.  Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.

[12]  R. Barst,et al.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.

[13]  A. Branzi,et al.  Primary Pulmonary Hypertension , 1998 .

[14]  M. Humbert,et al.  Pulmonary vascular disorders in portal hypertension. , 1998, The European respiratory journal.

[15]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[16]  Y. Okano,et al.  Orally active prostacyclin analogue in primary pulmonary hypertension , 1997, The Lancet.

[17]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[18]  S. Nishio,et al.  Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. , 1996, Journal of cardiovascular pharmacology.

[19]  E. Trulock,et al.  Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  C. Benjamin,et al.  Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. , 1995, Molecular pharmacology.

[21]  R. Gryglewski.  Interactions between endothelial mediators. , 1995, Pharmacology & toxicology.

[22]  G. Simonneau,et al.  Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. , 1994, Circulation.

[23]  G. Pietra.  Histopathology of primary pulmonary hypertension. , 1994, Chest.

[24]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[25]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[26]  D. Badesch,et al.  Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. , 1989, American journal of respiratory cell and molecular biology.

[27]  B. Groves,et al.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.

[28]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[29]  G. Borg.  Psychophysical bases of perceived exertion. , 1982, Medicine and science in sports and exercise.

[30]  J. Vane,et al.  An Enzyme Isolated from Arteries Transforms Prostaglandin Endoperoxides to an Unstable Substance that Inhibits Platelet Aggregation. , 1977 .